Compare Hims and Hers Health Inc (HIMS) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs US Bancorp — how do they compare? Hims and Hers Health Inc trades at $32.93 (market cap $7.57B), while US Bancorp trades at $63.93 (market cap $98.36B). The key difference: US Bancorp is far larger — about 13× Hims and Hers Health Inc's market cap, and US Bancorp pays a 3.29% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | USB | |
|---|---|---|
Market Cap | $7.57B | $98.36B |
Sector | Health | Financials |
52-Week High | $66.18 | $64.01 |
52-Week Low | $14.52 | $43.94 |
Enterprise Value | $7.95B | — |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
U.S. Bancorp (USB) trades at $63.09, down 0.08% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $69.70. Recent Q2 2026 earnings beat expectations with EPS of $1.35, driven by loan growth and fee income. Revenue reached a record $28.54B in 2025, with net income margin improving to 27.61%. The stock shows strong institutional support with 47.92% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and dividend yield near 3%, but risks include rising debt-to-asset ratios and macroeconomic sensitivity. Upside potential exists if loan growth and digital banking adoption continue, though investor caution is warranted given RSI levels indicating mild overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
